{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:57:51Z","timestamp":1790639871318,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Jena","id":[{"id":"https:\/\/ror.org\/035rzkx15","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inclisiran, a small interfering RNA targeting PCSK9, has demonstrated durable LDL-C lowering in clinical trials. However, real-world evidence on its long-term effectiveness and treatment persistence remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate LDL-C reductions, treatment persistence, and reasons for therapy discontinuation over a follow-up period of up to 3\u00a0years in a real-world lipid clinic cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed data from ten lipid clinics participating in the German Inclisiran Network (GIN). Adults with at least one inclisiran dose and follow-up lipid measurements were included. LDL-C levels were assessed during 3\u00a0years of follow-up (median 33\u00a0months, IQR 27\u201339). Discontinuation rates, therapy changes, and adverse effects were documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 109 patients (mean age 63.8\u00a0years, 43.1% female). The cohort comprised a heterogeneous population, with only\u2009~\u200930% receiving statins due to statin intolerance. Median (95% CI) LDL-C reduction from baseline to nadir was\u2009\u2212\u200946% (\u2212\u200960.8 to\u2009\u2212\u200933.8%). Median for LDL-C reduction for each individual during the follow-up was\u2009\u2212\u200928% (\u2212\u200933.8 to\u2009\u2212\u200924.2%). High interindividual and intraindividual variability in LDL-C response was observed. Over 3\u00a0years,\u2009~\u200930% of patients discontinued inclisiran, most commonly due to lack of efficacy (15.6%), adverse effects (7.3%), or a combination of both (1.8%). Those who discontinued due to lack of efficacy were older and had less background lipid-lowering therapy. Females were more likely than males to discontinue due to adverse effects. In a multivariable logistic regression model, older age was a predictor of higher discontinuation rates, whereas concomitant LLT use was associated with lower discontinuation rates. Notably,\u2009~\u200987% of patients with statin intolerance did not exhibit any adverse effects with inclisiran.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a heterogeneous real-world population, inclisiran achieved significant LDL-C reductions but with marked inter- and intraindividual variability. A notable proportion of patients discontinued therapy, highlighting the importance of individualized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-026-03028-9","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:52:11Z","timestamp":1790592731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term LDL-C lowering and treatment persistence with inclisiran: 3-year follow-up from the German Inclisiran Network"],"prefix":"10.1007","author":[{"given":"Umidakhon","family":"Makhmudova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Stuerzebecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"K\u00e4stner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Mensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Arndt","family":"Geiling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Haertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Stach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"B\u00e4ssler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sinning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Kassner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Steinhagen-Thiessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Christian","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0236-206X","authenticated-orcid":false,"given":"Oliver","family":"Weing\u00e4rtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"3028_CR1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 38:2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144","journal-title":"Eur Heart J"},{"key":"3028_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L (2019) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"3028_CR3","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferri\u00e8res J, Laufs U (2023) Treatment gaps in the implementation of LDL cholesterol control among high-and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. The Lancet Regional Health-Europe. 29:100624. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100624","journal-title":"The Lancet Regional Health-Europe."},{"key":"3028_CR4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G (2021) EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol 28:1279\u201389. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047","journal-title":"Eur J Prev Cardiol"},{"key":"3028_CR5","doi-asserted-by":"publisher","first-page":"100981","DOI":"10.1016\/j.lanepe.2024.100981","volume":"43","author":"PE St\u00fcrzebecher","year":"2024","unstructured":"St\u00fcrzebecher PE, Gouni-Berthold I, Mateev C, Frenzel O, Erbe S, Boeckel J-N (2024) Quality of life in patients with statin intolerance: a multicentre prospective registry study. Lancet Reg Health - Eur. 43:100981. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100981","journal-title":"Lancet Reg Health - Eur."},{"key":"3028_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN (2021) Inclisiran: first approval. Drugs 81:389\u2013395. https:\/\/doi.org\/10.1007\/s40265-021-01473-6","journal-title":"Drugs"},{"key":"3028_CR7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP (2020) Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 382:1507\u20131519. https:\/\/doi.org\/10.1056\/NEJMoa1912387","journal-title":"N Engl J Med"},{"key":"3028_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-023-02247-8","author":"U Makhmudova","year":"2023","unstructured":"Makhmudova U, Schatz U, Perakakis N, Kassner U, Schumann F, Axthelm C (2023) High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany. Clin Res Cardiol. https:\/\/doi.org\/10.1007\/s00392-023-02247-8","journal-title":"Clin Res Cardiol"},{"key":"3028_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2023.09.005","author":"JWCM Mulder","year":"2023","unstructured":"Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE (2023) First clinical experiences with inclisiran in a real-world setting. J Clin Lipidol. https:\/\/doi.org\/10.1016\/j.jacl.2023.09.005","journal-title":"J Clin Lipidol"},{"key":"3028_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2022-002184","volume":"9","author":"P Padam","year":"2022","unstructured":"Padam P, Barton L, Wilson S, David A, Walji S, de Lorenzo F, Ray KK, Jones B, Cegla J (2022) Lipid lowering with inclisiran: a real-world single-centre experience. Open Heart 9:e002184. https:\/\/doi.org\/10.1136\/openhrt-2022-002184","journal-title":"Open Heart"},{"key":"3028_CR11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jacc.2024.10.106","volume":"85","author":"P Gargiulo","year":"2025","unstructured":"Gargiulo P, Marzano F, Crisci M, Marcucci R, Bruzzese D, Maloberti A (2025) Real-world efficacy and safety of inclisiran. J Am Coll Cardiol 85:536\u201340. https:\/\/doi.org\/10.1016\/j.jacc.2024.10.106","journal-title":"J Am Coll Cardiol"},{"key":"3028_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.06.015","author":"D Mazdeyasnan","year":"2025","unstructured":"Mazdeyasnan D, Birs A, Chiou T, Diano L, Wilkinson MJ (2025) Insights from a real-world experience with inclisiran at a large United States lipid clinic. J Clin Lipidol. https:\/\/doi.org\/10.1016\/j.jacl.2025.06.015","journal-title":"J Clin Lipidol"},{"key":"3028_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/ehjcvp\/pvw006","volume":"2","author":"BW Karlson","year":"2016","unstructured":"Karlson BW, Wiklund O, Palmer MK, Nicholls SJ, Lundman P, Barter PJ (2016) Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother 2:212\u2013217. https:\/\/doi.org\/10.1093\/ehjcvp\/pvw006","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"3028_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.32604\/chd.2025.070423","volume":"20","author":"M Me\u00f1aca-Puentes","year":"2025","unstructured":"Me\u00f1aca-Puentes M, Arias-Ospina J-C, Galeano NF, Tabares-Soto R, Villa CAR (2025) Genetic factors influencing response to lipid-lowering therapies in atherosclerotic cardiovascular disease: systematic review. Congenit Heart Dis 20:743\u2013767. https:\/\/doi.org\/10.32604\/chd.2025.070423","journal-title":"Congenit Heart Dis"},{"key":"3028_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.atherosclerosis.2021.03.024","volume":"328","author":"BA Griffin","year":"2021","unstructured":"Griffin BA, Mensink RP, Lovegrove JA (2021) Does variation in serum LDL-cholesterol response to dietary fatty acids help explain the controversy over fat quality and cardiovascular disease risk? Atherosclerosis 328:108\u2013113. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.03.024","journal-title":"Atherosclerosis"},{"key":"3028_CR16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.164.8.863","volume":"164","author":"IS Ockene","year":"2004","unstructured":"Ockene IS, Chiriboga DE, Stanek IEJ, Harmatz MG, Nicolosi R, Saperia G (2004) Seasonal variation in serum cholesterol levels: treatment implications and possible mechanisms. Arch Intern Med 164:863. https:\/\/doi.org\/10.1001\/archinte.164.8.863","journal-title":"Arch Intern Med"},{"key":"3028_CR17","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s00392-023-02257-6","volume":"113","author":"W Koenig","year":"2024","unstructured":"Koenig W, Lorenz ES, Beier L, Gouni-Berthold I (2024) Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany. Clin Res Cardiol 113:812\u201321. https:\/\/doi.org\/10.1007\/s00392-023-02257-6","journal-title":"Clin Res Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-03028-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-03028-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-03028-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:03:19Z","timestamp":1790636599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-03028-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":17,"alternative-id":["3028"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-03028-9","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M. reports speaker fee from Novartis, non-financial support from Novartis, Sanofi and Roche Diagnostics. A.V. reports speaker fees and\/or advisory board honoraria from Aegerion, Akcea, Amgen, Amryt, Berlin Chemie, Chiesi, Daiichi Sankyo, MSD, Novartis, Regeneron\/Sanofi. D.S. reports speaker fees from Novartis, Daiichi Sankyo und Amgen. U.K. reports fees from Amgen, Daiichi Sankyo, Novartis, Regeneron\/Sanofi. E.S-T. reports fees for lectures and\/or advisory board honoraria from Fresenius Medical Care. Daiichi-Sankyo, Novartis, Amgen, Amarin, Sanofi, Pfizer. U.L. reports fees from Novartis, Daiichi Sankyo, Amgen, Sanofi. O.W. reports fees from Novartis, Daiichi Sankyo, Amgen, Sanofi, Fresenius, Novo Nordisk, Hexal, Akcea Therapeutics, Sobi and Pfizer. All reported conflicts of interest are outside the submitted work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}